Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fitusiran - Alnylam Pharmaceuticals/Sanofi

Next Previous
Drug Profile

Fitusiran - Alnylam Pharmaceuticals/Sanofi

Alternative Names: ALN-AT3; ALN-AT3SC; Qfitlia; SAR-439774

Latest Information Update: 31 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Sanofi
  • Class Amides; Amino sugars; Antihaemorrhagics; Drug conjugates; Small interfering RNA
  • Mechanism of Action Antithrombin III expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A; Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Haemophilia A; Haemophilia B

Most Recent Events

  • 28 Mar 2025 Registered for Haemophilia A (In adults, In the elderly, In adolescents) in USA (SC) - First global approval
  • 28 Mar 2025 Registered for Haemophilia B (In adolescents, In adults, In the elderly) in USA (SC) - First global approval
  • 28 Mar 2025 Sanofi expects a regulatory decision for fitusiran in Haemophilia A and Haemophilia B in China in the second half of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top